[Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
Lymphocytes isolated from malignant pleural effusions of patients with advanced lung cancer or from allogenic peripheral blood of healthy donors were induced to become LAK cells after in vitro culture with rIL-2. One hundred and twenty-one patients with malignant effusions were treated by intrapleural administration of autologous or allogenic LAK cells combined with rIL-2. The effusions disappeared in 71 (58.6%) patients and significantly decreased in 45 (36.2%) patients. Five patients did not respond to the treatment. Tumor cells in pleural effusions disappeared or significantly decreased and lymphocytes significantly increased in all responders. Except for transient chill and/or fever in 102 patients, no serious side effect was found. The results indicate that transfer of autologous or allogenic LAK cells combined with rIL-2 in the treatment of patients with malignant pleural effusions due to advanced lung cancer is feasible effective, and safe.
Liu
X
X
Institute of Oncology, Harbin Medical University.
D000230:Adenocarcinoma / Q000150:complications*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000150:complications; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008175:Lung Neoplasms / Q000150:complications*; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins